TY - JOUR
T1 - Amyloidosis
T2 - Diagnosis and management
AU - Gertz, Morie A.
AU - Lacy, Martha Q.
AU - Dispenzieri, Angela
AU - Hayman, Suzanne R.
N1 - Funding Information:
This work was supported in part by the Hematologic Malignancies Fund, Mayo Clinic.
PY - 2005/11
Y1 - 2005/11
N2 - Amyloidosis is a rare plasma cell proliferative disorder. The annual incidence in Olmsted County, Minnesota, is 8 in 1,000,000 patients. This is a difficult disorder to diagnose, because the symptoms at presentation are vague and include dyspnea, paresthesias, edema, weight loss, and fatigue. The clinical syndromes at the time of presentation include nephrotic-range proteinuria with or without renal failure, cardiomyopathy, "atypical multiple myeloma," hepatomegaly, and autonomic or peripheral neuropathy. The serum immunoglobulin free light chain assay has been an important step forward in classifying systemic amyloidosis as an immunoglobulin light chain form and in monitoring therapy. Recently, the importance of serum cardiac biomarkers in assessing outcome has been recognized. New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide.
AB - Amyloidosis is a rare plasma cell proliferative disorder. The annual incidence in Olmsted County, Minnesota, is 8 in 1,000,000 patients. This is a difficult disorder to diagnose, because the symptoms at presentation are vague and include dyspnea, paresthesias, edema, weight loss, and fatigue. The clinical syndromes at the time of presentation include nephrotic-range proteinuria with or without renal failure, cardiomyopathy, "atypical multiple myeloma," hepatomegaly, and autonomic or peripheral neuropathy. The serum immunoglobulin free light chain assay has been an important step forward in classifying systemic amyloidosis as an immunoglobulin light chain form and in monitoring therapy. Recently, the importance of serum cardiac biomarkers in assessing outcome has been recognized. New therapies developed over the past 5 years include high-dose chemotherapy with stem cell reconstitution, combinations of alkylating agents with dexamethasone, and, most recently, thalidomide.
KW - Amyloid
KW - Monoclonal gammopathy
KW - Multiple myeloma
KW - Stem cell transplantaion
UR - http://www.scopus.com/inward/record.url?scp=33644877690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644877690&partnerID=8YFLogxK
U2 - 10.3816/CLM.2005.n.048
DO - 10.3816/CLM.2005.n.048
M3 - Review article
C2 - 16354326
AN - SCOPUS:33644877690
SN - 1557-9190
VL - 6
SP - 208
EP - 219
JO - Clinical Lymphoma and Myeloma
JF - Clinical Lymphoma and Myeloma
IS - 3
ER -